Farallon Capital Management's 13F filing for the first quarter of 2026, disclosed on August 14, 2026, reveals a significant portfolio update with a reported value of $1.52 billion in managed securities. The filing shows a substantial increase in the firm's Electronic Arts (EA) position, which curiously accounts for the entire reported value. This concentration occurred alongside the initiation of several new, high-value positions, suggesting a dynamic period of capital allocation for the major investment firm.
The most prominent changes include several large new entries, signaling a bullish stance on the technology and biotechnology sectors. Farallon established a major new position in Revolution Medicines (RVMD) valued at $1.32 billion. It also made significant new investments in tech giants Amazon (AMZN) and Microsoft (MSFT), with stakes valued at $878.56 million and $867.97 million, respectively. Further new buys included insurance broker Aon PLC and biotech firm BridgeBio Pharma, diversifying the new wave of investments.
These aggressive new positions, coupled with the increased concentration in Electronic Arts, mark a strategic repositioning for Farallon. While 13F filings are a snapshot of long holdings and don't reflect short positions or other assets, the scale of these new investments offers a glimpse into the firm's evolving market strategy. Note that the reported total portfolio value appears inconsistent with the individual values of the new holdings, which could be due to specific reporting methodologies for certain assets.